Compare Southwest Airlines Co (LUV) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Novo Nordisk A/S — how do they compare? Southwest Airlines Co trades at $41.33 (market cap $20.23B), while Novo Nordisk A/S trades at $38.45 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 8.2× Southwest Airlines Co's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 65 Days and Novo Nordisk A/S for 116 Days on average.
| LUV | NVO | |
|---|---|---|
Market Cap | $20.23B | $165.31B |
Volume | 14,560,422 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $54.80 | $63.98 |
52-Week Low | $29.67 | $35.29 |
Typical Hold Time | 65 Days | 116 Days |
Enterprise Value | $23.33B | $179.56B |
Dividend Yield | 1.74% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $41.15, down 1.37% on the day, amid a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 25.85 and net income margin of 2.78%, while cash flow trends indicate a projected recovery in 2026. Recent news highlights the company's commercial transformation initiatives, including new fare structures and lounge plans, aiming to boost profitability.
Outlook remains cautiously optimistic with a consensus price target of $49.61, suggesting upside potential, though risks include volatile fuel costs and competitive pressures. The stock's valuation appears reasonable relative to sales, but investors should weigh near-term operational headwinds against long-term strategic gains.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
